Immunomodulators
In this section you will find Therapeutics Line of Treatment Immunomodulators market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.
9 Item(s)
per page
-
Analytical Tool - Cancer Therapeutic Antibodies
€3,949.00Published by BioSeeker Group on Sep 27th, 2011A unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer antibody R&D and business development. Learn More -
Analytical Tool - Cancer Immunotherapy
€5,950.00Published by BioSeeker Group on Feb 1st, 2011A unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer immunotherapy. Learn More -
Immunotherapy in Oncology Drug Pipeline Update 2011
€2,450.00Published by BioSeeker Group on Feb 1st, 2011There are today 473 (421) companies plus partners developing 978 (783) cancer immunotherapy drugs in 1959 (1573) developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 333 (334) drugs. Immunotherapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 336 (315) different targets. Learn More -
Cancer Vaccines Drug Pipeline Update 2011
€1,499.00Published by BioSeeker Group on Feb 1st, 2011There are today 216 (195) companies plus partners developing 278 (209) cancer vaccine drugs in 500 (343) developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 168 (173) drugs. Cancer Vaccines Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 110 (97) different targets. Learn More -
Cytokine Therapy in Oncology Drug Pipeline Update 2011
€999.00Published by BioSeeker Group on Feb 1st, 2011There are today 83 (69) companies plus partners developing 104 (70) cytokine drugs in 205 (139) developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 6 (5) drugs. Cytokine Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 20 (19) different targets. Learn More -
Antibodies in Oncology Drug Pipeline Update 2011
€1,499.00Published by BioSeeker Group on Feb 1st, 2011There are today 294 (248) companies plus partners developing 613 (472) antibody drugs in 1241 (947) developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 291 (285) drugs. Antibodies In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 260 (229) different targets. Learn More -
Immunotherapy in Oncology: Gaining Momentum
€2,950.00Published by BioSeeker Group on Aug 4th, 2006The immunotherapy field in cancer has never been more potent than it is right now, including block buster drugs like Avastin, Erbitux, and Rituxan. Antibodies are making the headlines but cancer vaccines are not far away. The recent approval of Gardasil, a cervical cancer vaccine, will certainly become a strong representative of its kind. Future challenges for the industry lie in discovering strong antigens, effective immunomodulators and developing suitable delivery technologies. Learn More -
Competitive Outlook on Non-Antibody Based Cancer Vaccines
€1,950.00Published by BioSeeker Group on Aug 3rd, 2006Research and development in the cancer vaccine field is dominated by its top 10 players, interestingly not including any of the big pharma companies per se. The recent Gardasil approval and GlaxoSmithKline’s acquisition of Corixa will certainly push the industry towards more acquisitions. With this in mind, this report makes an in-depth assessment of competitive landscape, tumor antigen technologies, immunostimulatory strategies, vaccine delivery technologies, and a progress analysis of six major cancer vaccine indications. Learn More -
The Commercial Success of Cancer Therapeutic Antibodies - The Formation of a Second Wave
€1,950.00Published by BioSeeker Group on Nov 22nd, 2005The blockbuster drugs Rituxan, Avastin, and Erbitux have change the way the industry looks upon antibody treatment of cancer in the same way that Taxol changed the way pharmaceutical companies look at the possibilities in the field of cancer therapeutics. Learn More
9 Item(s)
per page